Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53.

Cell death & disease - 7 May 2020

Hu Chen, Zhang Mu, Moses Niko, Hu Cong-Li, Polin Lisa, Chen Wei, Jang Hyejeong, Heyza Joshua, Malysa Agnes, Caruso Joseph A, Xiang Shengyan, Patrick Steve, Stemmer Paul, Lou Zhenkun, Bai Wenlong, Wang Chuangui, Bepler Gerold, Zhang Xiaohong Mary

Abstract excerpt

Ubiquitin-specific peptidase 10 (USP10) stabilizes both tumor suppressors and oncogenes in a context-dependent manner. However, the nature of USP10's role in non-small cell lung cancer (NSCLC) remains unclear. By analyzing The Cancer Genome Atlas (TCGA) database, we have shown that high levels of USP10 are associated with poor overall survival in NSCLC with mutant p53, but not with wild-type p53. Consistently,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cisplatin
Share to Gene Knockdown Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, SCID

Share to Platinum

Share to Protein Stability

Share to Ubiquitin Thiolesterase

Share to Ubiquitination

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 32382008
DOI: 10.1038/s41419-020-2519-8
PMCID: PMC7206099

Genes

USP10
HDAC6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53.PMID 32382008Read ↗

Targeting USP13 ‐mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in non‐small cell lung cancerSemantic proximity Read ↗

USP8 Is a Novel Target for Overcoming Gefitinib Resistance in Lung CancerSemantic proximity Read ↗

Ubiquitin-specific peptidase 10, a deubiquitinating enzyme: Assessing its role in tumor prognosis and immune responseSemantic proximity Read ↗

USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapy.Semantic proximity Read ↗

USP10 Antagonizes c-Myc Transcriptional Activation through SIRT6 Stabilization to Suppress Tumor FormationSemantic proximity Read ↗

USP14 Regulates DNA Damage Response and Is a Target for Radiosensitization in Non-Small Cell Lung CancerSemantic proximity Read ↗

USP28 promotes tumorigenesis and cisplatin resistance by deubiquitinating MAST1 protein in cancer cellsSemantic proximity Read ↗

USP28 deletion and small molecule inhibition destabilises c-Myc and elicits regression of squamous cell lung carcinomaSemantic proximity Read ↗

Over-Expression of Deubiquitinating Enzyme USP14 in Lung Adenocarcinoma Promotes Proliferation through the Accumulation of β-CateninSemantic proximity Read ↗

USP29 enhances chemotherapy-induced stemness in non-small cell lung cancer via stabilizing Snail1 in response to oxidative stressSemantic proximity Read ↗

USP2 reversed cisplatin resistance through p53-mediated ferroptosis in NSCLCSemantic proximity Read ↗

USP4 expression independently predicts favorable survival in lung adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.